Rhabdomyolysis during adjunctive treatment with cariprazine in a clozapine-resistant schizophrenia patient.
Int Clin Psychopharmacol
; 39(4): 288-290, 2024 Jul 01.
Article
en En
| MEDLINE
| ID: mdl-38170806
ABSTRACT
We report the case of a 49-year-old male treatment-resistant schizophrenia patient, whose treatment with clozapine and sertraline was supplemented with cariprazine 1.5â
mg/day while regularly presenting for electroconvulsive therapy. After 3 weeks of adjunctive treatment with cariprazine, blood tests revealed pronounced signs of rhabdomyolysis, including a creatine kinase serum level of 20â
386 U/L and an AST serum level of 696 U/L. Clinically, the patient did not report somatic symptoms other than mild back pain. After discontinuation of cariprazine and normal saline infusion, the above-mentioned findings resolved rapidly. Although very rare, rhabdomyolysis can be a potentially dangerous side effect of cariprazine and clinicians should be aware of its possible occurrence.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Piperazinas
/
Rabdomiólisis
/
Antipsicóticos
/
Clozapina
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Int Clin Psychopharmacol
Asunto de la revista:
PSICOFARMACOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Austria